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The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic
Anti-Norovirus Activity and Clears Cells from the Norovirus Replicon
J. Rocha-Pereira,a,b M. S. J. Nascimento,a Q. Ma,c,d R. Hilgenfeld,c,d J. Neyts,b D. Jochmansb
L. Microbiologia, D. Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugala; Rega Institute for Medical Research, University of Leuven, Leuven,
Belgiumb; Institute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Lübeck, Lübeck, Germanyc; German Center for Infection Research
(DZIF), University of Lübeck, Lübeck, Germanyd
Potent and safe inhibitors of norovirus replication are needed for the treatment and prophylaxis of norovirus infections. We
here report that the in vitro anti-norovirus activity of the protease inhibitor rupintrivir is extended to murine noroviruses and
that rupintrivir clears human cells from their Norwalk replicon after only two passages of antiviral pressure. In addition, we
demonstrate that rupintrivir inhibits the human norovirus (genogroup II [GII]) protease and further explain the inhibitory ef-
fect of the molecule by means of molecular modeling on the basis of the crystal structure of the Norwalk virus protease. The
combination of rupintrivir with the RNA-dependent RNA polymerase inhibitors 2=-C-methylcytidine and favipiravir (T-705)
resulted in a merely additive antiviral effect. The fact that rupintrivir is active against noroviruses belonging to genogroup I
(Norwalk virus), genogroup V (murine norovirus), and the recombinant 3C-like protease of a GII norovirus suggests that the
drug exerts cross-genotypic anti-norovirus activity and will thus most likely be effective against the clinically relevant human
norovirus strains. The design of antiviral molecules targeting the norovirus protease could be a valuable approach for the treat-
ment and/or prophylaxis of norovirus infections.
Human noroviruses are a major cause of food-borne illness,accountable for 50% of all-etiologies outbreaks of acute gas-
troenteritis (both in developing and developed countries) (1, 2).
Outbreaks often occur in long-term-care facilities and hospitals
where the elderly and immunocompromised can become severely
ill. The vast spreading nature of this virus commonly results in
hundreds of sick individuals in each setting and may lead to the
closure of hospital wards (3, 4). Associations with chronic gastro-
intestinal problems and cases of chronic gastroenteritis caused by
noroviruses are being increasingly recognized (5, 6). There is no
vaccine or antiviral treatment available against norovirus infec-
tions. Rupintrivir (AG-7088) is a protease inhibitor originally de-
veloped for the treatment of human rhinovirus infections (7, 8).
Activity has also been demonstrated against other picornaviruses
as well as against coronaviruses and caliciviruses (9, 10). Human
noroviruses belong to theCaliciviridae family, whose protease dis-
plays a chymotrypsin-like fold with a cysteine as the active-site
nucleophile and shares similarities with the 3C protease of picor-
naviruses (11). Rupintrivir has recently been reported to inhibit
the replication of the Norwalk virus replicon (a genogroup I [GI]
human norovirus) (10).
We here confirm and further document the inhibitory effect of
rupintrivir against the human norovirus (by demonstrating that
the compound is able to clear cells from the replicon) and dem-
onstrate that the drug is antivirally active against the murine no-
rovirus (MNV), a virus belonging to another genogroup of the
genus. We study the inhibitory effect of rupintrivir against a GII
3C-like protease (in an enzymatic assay) and explain at the struc-
tural level the potential interactions between the inhibitor and the
enzyme. The fact that the compound inhibits noroviruses of dif-
ferent genogroups suggests that the compound exerts cross-geno-
typic anti-norovirus activity and will very likely also be effective
against other genogroups of the genusNorovirus, for which no cell
culture system is currently available.
MATERIALS AND METHODS
Cells, viruses, and compound.HG23 cells (Norwalk virus replicon-bear-
ing Huh-7 origin) were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Life Technologies, Ghent, Belgium) supplemented with 10%
fetal bovine serum (FBS), 2mML-glutamine, 20mMHEPES, 0.075 g/liter
sodium bicarbonate, 100 U penicillin/ml, and 100 g/ml streptomycin at
37°C and 1.25 mg/ml of Geneticin (G418; Life Technologies) in a humid-
ified atmosphere of 5%CO2.MNV (virus strainMNV-1.CW1) was prop-
agated in RAW 264.7 cells grown in DMEM (Life Technologies, Ghent,
Belgium) supplemented with 10% or 2% FBS, 2mM L-glutamine, 20mM
HEPES, 0.075 g/liter sodium bicarbonate, 1 mM sodium pyruvate, 100 U
penicillin/ml, and 100g/ml streptomycin at 37°C in a humidified atmo-
sphere of 5% CO2. Rupintrivir was a kind gift of Pfizer (La Jolla, CA).
Antiviral assay with the Norwalk replicon. The inhibitory effect of
rupintrivir on human norovirus replication was assessed by quantifica-
tion of the levels of Norwalk replicon RNA and of the reference (house-
keeping) gene -actin mRNA (by quantitative reverse transcription-PCR
[qRT-PCR]). To this end, HG23 cells (5,000 cells/well) were seeded in
96-well plates in complete DMEM without the selection marker G418.
Following an incubation period of 24 h, a serial dilution of rupintrivir was
added to the cultures. After 72 h of incubation, cell monolayers were
washed with phosphate-buffered saline (PBS) and collected for quantifi-
cation of RNA load by qRT-PCR. Intracellular RNA was extracted from
cells using the cell-to-cDNA lysis buffer (Ambion; Life Technologies). For
detection of Norwalk virus replicon RNA, forward (5=-CCG GCT ACC
TGCCCA TTC-3=) and reverse (5=-CCAGATCATCCTGATCGACAA
G-3=) primers and probe (5=-FAM-ACATCGCATCGAGCGAGCACG
TAC-TAMRA-3=; FAM is 6-carboxyfluorescein and TAMRA is 6-car-
Received 27 November 2013 Returned for modification 23 December 2013
Accepted 26 May 2014
Published ahead of print 2 June 2014
Address correspondence to J. Neyts, johan.neyts@rega.kuleuven.be.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.02546-13
August 2014 Volume 58 Number 8 Antimicrobial Agents and Chemotherapy p. 4675–4681 aac.asm.org 4675
 o
n
 July 25, 2014 by KU Leuven University Library
http://aac.asm
.org/
D
ow
nloaded from
 
boxytetramethylrhodamine) for the neomycin gene were used, as previ-
ously described (12). For detection of -actin mRNA, forward (5=-GGC
ATC CAC GAA ACT ACC TT-3=) and reverse (5=-AGC ACT GTG TTG
GCG TAC AG-3=) primers and probe (5=-HEX-ATC ATG AAG TGT
GAC GTG GAC ATC CG-BHQ1–3=) were used, as previously described
(13). One-step qRT-PCRwas performed in a 25-l reactionmixture con-
taining 12.5 l One-Step reverse transcriptase qPCRmaster mix plus low
ROX (Eurogentec, Belgium), 0.125 l of RT-PCR enzyme mix, 5 l of
template RNA, and either 300 nMNorwalk replicon primers and probe or
300 nM -actin primers and 200 nM probe. Cycling conditions were
reverse transcription at 48°C for 30 min, initial denaturation at 95°C for
10min, followed by 40 cycles of denaturation at 95°C for 15 s and anneal-
ing and extension at 60°C for 1 min (ABI 7500 Fast real-time PCR
system; Applied Biosystems, USA). To determine the relative expres-
sion levels of Norwalk replicon RNA, -actin was used as a normalizer
and ratios were calculated using the Pfafflmethod (14). The expression
ratio (Norwalk replicon/-actin) was calculated as expression ratio
(ENorwalk)
CT, Norwalk (CC – TC)/(E-actin)
CT, -actin (CC – TC), where
ENorwalk andE-actin represent theamplificationefficiency (E10
1/slope) for
theNorwalk replicon and-actin qRT-PCRs, respectively.CT, Norwalk
(CC – TC) is the cycle threshold (CT) of untreated control cells (CC)
minus the CT of cells treated with a compound concentration (TC) ob-
tainedwithNorwalk replicon primers and probe.CT,-actin (CC–TC)
is theCT of untreated CCminus theCT of cells treated with a TC obtained
with -actin primers and probe. Efficiency values (ENorwalk and E-actin)
were determined for each qRT-PCR. The 50% and 90% effective concen-
trations (EC50 and EC90) were defined as the compound concentration
that resulted in 50% and 90% reductions of the relative Norwalk replicon
RNA levels.
Clearance rebound assay.HG23 cells were seeded (2.5 105 cells) in
25 cm2 T-flasks. One day later, cell culture medium was replaced for
DMEM without G418 containing either a fixed concentration (not
cytostatic) of rupintrivir (0.1, 1, 10 M) or no antiviral compound.
When 90% confluent, cells were trypsinized and (i) 2.5 105 cells were
seeded in a new 25-cm2 T-flask with the same concentration of com-
pound while (ii) 1.5  105 cells from each flask were collected for
quantification of replicon/-actin RNA. In total, cells were passaged
five consecutive times in the presence or absence of rupintrivir and in
the absence of G418 (clearance phase). For the rebound phase, after
clearance passages 2, 4, and 5, cells of each flask were passaged (when
90% confluent) for three consecutive times in the presence of 1.25
mg/ml G418 and in the absence of rupintrivir. Also here, (i) 2.5 105
cells were seeded in new 25-cm2 T-flasks and (ii) 1.5  105 cells from
each flask was collected for quantification of replicon/-actin RNA by
qRT-PCR. Whereas cultures that have been completely cleared from
their replicon will lose the ability to grow in the presence of G418,
cultures that still carry the replicon will survive and proliferate again in
the presence of the selection marker.
Antiviral and cytotoxicity assay with MNV. The anti-norovirus ac-
tivity of rupintrivir was determined using an MTS [3-(4,5-dimethy-
lthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium]-based cytopathic effect (CPE) reduction assay in the MNV/
RAW 264.7 model, as previously described (15). Briefly, RAW 264.7 cells
were seeded (1 104 cells/well) in 96-well plates and infected with MNV
(virus strainMNV-1.CW1) at amultiplicity of infection (MOI) of 0.001 in
the presence (or absence) of a dilution series of rupintrivir (0.1 to 200
M). Following 3 days of incubation, cell culture supernatants were col-
lected for quantification of viral RNA load by qRT-PCRwithMNV prim-
ers and probe as described elsewhere (15). For the MTS reduction assay,
75 l of MTS-phenazine methosulfate (PMS) solution was added to each
well, and the optical density was read at 498 nm (OD498) 2 h later. The
EC50 was defined as the compound concentration that (i) protected 50%
of cells fromvirus-inducedCPEor (ii) reducedMNVRNAcopies by 50%.
Adverse effects of the drug on the host cell were also assessed by means of
theMTSmethod, by exposing uninfected cells to the same concentrations
of rupintrivir for 3 days. The CC50 was defined as the compound concen-
tration that reduced the number of viable cells by 50%.
Recombinant production of the norovirus GII 3C-like protease.
DNA coding for the norovirus 3C-like protease (GII, strain Norovirus
Hu/NLV/Dresden174/pUS-NorII/1997/GE) was amplified from the
genomic cDNA (kindly provided by J. Rohayem, Riboxx) using the PCR
method (forward primer, 5=-AAA ACC ATG GCC CCA CCA AGC ATC
TGG TCG AGG-3=; reverse primer, 5=-AAA AGG TAC CTT ATT CAA
GTG TAG CCT CCC CCT CAC TC-3=) and inserted into the NcoI
and KpnI sites of the pETM10 vector (a kind donation by EMBL,
Hamburg). The gene was overexpressed in the Escherichia coli strain
Rosetta(DE3)pLysS, by induction with 0.5 mM isopropyl--D-thiogalac-
topyranoside (IPTG) when cells had reached an OD600 of 0.6 at 37°C.
Subsequently, the cells were further incubated overnight at 20°C, resulting
in a protein comprising amino acid residues 1 to 188 of the norovirus
3C-like protease, with the extra sequence MKHHHHHHPM at its N ter-
minus derived from the vector. Cells were harvested by centrifugation and
broken by sonication in buffer A (50 mM Tris-HCl [pH 8.0], 500 mM
NaCl, 0.02% [vol/vol] -mercaptoethanol [-ME], 10 mM imidazole).
The cell debris was clarified by centrifugation, and the resultant superna-
tant was applied to anNi-nitrilotriacetic acid (NTA) resin (Qiagen). After
washing the resin with 10 column volumes of buffer A, the protein was
eluted with 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 0.02% -ME, and
250 mM imidazole. Subsequently, the eluted protein was further purified
by gel filtration on HiLoad 16/600 Superdex 75 (GE Healthcare), with 20
mM HEPES (pH 7.4), 200 mM NaCl, and 2 mM dithiothreitol (DTT) as
the flowing buffer. The enzyme concentration was determined using the
absorption at 280 nm.
In vitro fluorescence assay of enzyme activity. The activity of the
enzyme was evaluated by measuring the fluorescent signal (excitation
wavelength of 360 nm, emission wavelength of 460 nm) of the dabcyl
group of the FRET substrate dabcyl-KDEFELQ2GPALT(D-edans)-
amide. Upon cleavage of the substrate at the site indicated by the arrow
(2), quenching of dabcyl fluorescence by the edans group is abolished.
The reaction buffer was 50 mM HEPES (pH 7.5), 50 mM NaCl, 0.5 mM
EDTA, 6 mM DTT, 60% (vol/vol) glycerol. Measurements were per-
formed in 100-l reaction volumes at 37°C using a BioTek FLx800micro-
plate fluorescence reader. For the determination of kcat and Km, substrate
concentrations of 1.25, 2.5, 5, 10, 20, and 40 M and an enzyme concen-
tration of 0.7 Mwere chosen. To assess the inhibitory activity of rupin-
trivir toward the norovirus 3C-like protease, the enzyme was preincu-
bated with various concentrations of rupintrivir (2.5, 5, 10, 20, 40, and 80
M) for 30 min at 37°C before 20 M substrate was added. Rupintrivir
was dissolved in dimethyl sulfoxide (DMSO), resulting in a total DMSO
concentration of less than 1.2% in the assay buffer, an amount that has
been shown previously to be well tolerated by norovirus 3C-like proteases
(16).
The principle of the kinetic assay andmore details have been described
elsewhere (17). Briefly, time-dependent progress curves were fitted to a
first-order exponential to obtain an observed first-order inhibition rate
constant (kobs) (18): F v0 ⁄kobs · 1 expkobs · t  D.
In this equation, F is the product fluorescence (measured in arbitrary
units), v0 is the initial velocity, t is time, and D is a displacement term
accounting for the nonzero emission at the start of data collection. Since
in the case of low enzyme activity the measurement of the rate of inacti-
vation, k3, by an irreversible inhibitor such as rupintrivir tends to be
difficult, kobs/[I], where [I] is the concentration of the inhibitor, was used
as an approximation of the pseudo-second-order rate constant.
Analysis of the enzyme kinetics was carried out using the GraphPad
Prism software and the nonlinear regression analysis program Origin
(OriginLab), in order to obtain the kobs values for enzyme inactivation at
three different inhibitor concentrations.
Molecular modeling. Atomic coordinates for rupintrivir were re-
trieved from PDB 3QZR (complex with the enterovirus 71 3C protease)
(19). Atomic coordinates for the Norwalk virus 3C-like protease were
Rocha-Pereira et al.
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retrieved from the crystal structure of a peptide aldehyde complex (PDB
4IMQ) (20). As this coordinate set lacks residues 123 to 132, these were
model-built using the SWISS-MODEL webserver (21). Rupintrivir was
manually docked into the substrate-binding cleft of the Norwalk virus
3CLpro using Coot (22), based on the knowledge of inhibitor-protein
interactions learned frombothPDB4IMQandPDB3QZR. Subsequently,
the coordinates of the complex were further optimized using the energy
minimization function of Yasara (http://www.yasara.org/). The intermo-
lecular contacts were analyzed with Ligplot (23).
Combination studieswith 2CMCandT-705.The combined antiviral
effects of rupintrivir with 2CMC and T-705 were studied. The effects of
drug-drug combinations were evaluated using the method of Prichard
and Shipman, through the Mac Synergy II software (24). The theoretical
additive effect is calculated from the dose-response curves of individual
molecules by the equationZXY(1X), whereX andY represent the
inhibition produced by the individual compounds and Z represents the
theoretical effect produced by the combination of compounds when ad-
ditive. The theoretical additive surface is subtracted from the actual ex-
perimental surface. When a combination is additive, data points of the
calculated surface form a horizontal surface that equals the zero plane. A
surface that lies	20%above the zero plane indicates a synergistic effect of
the combination; a surface	20% below the zero plane indicates antago-
nism. For both combinations studied (rupintrivir-2CMC and rupintri-
vir–T-705), a checkerboardwith 3-fold serial dilutions of compounds was
studied. These were added to HG23 cells (5,000 cells/well), preseeded 1
day earlier in 96-well plates. Following 72 h of incubation, cellmonolayers
were collected for quantification of RNA load by qRT-PCR.
RESULTS AND DISCUSSION
Rupintrivir inhibits the replication of theNorwalk replicon and
clears human cells from the replicon. The inhibitory effect of
rupintrivir on human norovirus replication was assessed by
quantification of the levels of Norwalk replicon RNA and of the
reference (housekeeping) gene -actin mRNA, by qRT-PCR.
Rupintrivir reduced the levels of Norwalk virus RNA in a dose-
dependent manner with an EC50 of 0.3
 0.1 M and an EC90 of
1.5
 0.2 M (Fig. 1). Such antiviral effect, although 10-fold less
pronounced, was also earlier reported (10); differences in the an-
tiviral activity in that and our study may possibly be related to
either differences in methodology or in the purity of the com-
pound. No decrease in -actin levels was observed at any tested
concentration, corroborating recently published data (10).
It was next studied whether rupintrivir is able to totally elimi-
nate the norovirus replicon from stably transfected cultures. For
that purpose, clearance and rebound experiments were per-
formed. During the clearance phase, a reduction of 3 log10 in Nor-
walk replicon RNA levels was observed in cultures treated with 10
M rupintrivir for a single passage; 7 log10 reductions in replicon
RNA levels were observed following 4 passages in the presence of
10 M of the compound (Fig. 2A). Treatment with 1 M rupin-
trivir resulted in a decrease in Norwalk RNA of 3 log10 following
three passages; at a concentration of 0.1M, the reduction of viral
RNA levels was 1.6 log10 after five passages. Cultures that have
been completely cleared from their replicon will lose in the re-
bound phase (during which G418 is added) the ability to prolifer-
ate, whereas cultures that still carry some replicon will survive and
proliferate in the presence of the selection marker. When chal-
lenged with G418, cells that had been cultured for two passages in
FIG 1 Antiviral activity of rupintrivir against the Norwalk virus replicon,
represented by relative genome quantification (Norwalk replicon/-actin).
Results are mean values (
standard errors of the means [SEM]) from 4 inde-
pendent experiments. The dotted lines represent 50 and 90% reduction of the
relative Norwalk replicon RNA levels.
FIG 2 Effect of rupintrivir on the clearance of the Norwalk replicon fromHG23 cells. (A) Clearance phase. Cells were treated for five consecutive passages with
3 concentrations of rupintrivir (10, 1, and 0.1M) in the absence of selective pressure with G418. (B) Rebound phase. During the rebound passages, rupintrivir
was omitted from the culture medium, but cells were again cultured under selective pressure with G418 (1.25 mg/ml). The graph shows the number of
cells/25-cm2 T-flasks for three rebound passages with cells from clearance passages 2, 4, and 5 (ND, not detected; NT, not tested). The dotted line represents the
minimum number to subcultivate cells again.
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the presence of either 1 or 10 M rupintrivir were no longer able
to proliferate in the presence of G418 (Fig. 2 B). Hence, treatment
for 9 days with 1 M rupintrivir is sufficient to clear cells from
their replicon. The inability of cells to proliferate once G418 is
added again could be due to a low degree of fitness of replicon
RNA following treatmentwith rupintrivir. Population sequencing
would have been necessary to assess if that was indeed the case. At
lower concentrations (0.1 M), cultures were not cleared, even
after five passages in the presence of the compound. It has been
demonstrated by selecting for drug-resistant variants that rupin-
trivir indeed targets the viral 3C protease. Resistance developed
slowly (unless what is observed for HCV protease inhibitors, for
example) with accumulation of multiple mutations in the rhino-
virus protease. The efficient clearance of the Norwalk replicon
from the host cell by rupintrivir suggests that resistance against
noroviruses may also develop slowly. Indeed, during HCV repli-
con clearance experiments with HCV protease inhibitors, resis-
tance developed readily, and clearance was, as a result, virtually
impossible (25).
The anti-norovirus activity of rupintrivir is extended to
MNV. To study whether rupintrivir exerts cross-genotypic noro-
virus activity, we next assessed whether the drug is able to inhibit
the replication ofMNV, a genogroup V norovirus.MNV has been
used as a surrogate for human noroviruses (given that these are
not cultivable) and shares many of their structural and replicative
features (26, 27). Rupintrivir inhibited in a dose-dependent man-
nerMNV-inducedCPE (EC50 13
 2M) (Fig. 3) (althoughno
activity was reported in another study [10]). We confirmed this
anti-norovirus activity by assessing the effect of rupintrivir on
MNV RNA synthesis; rupintrivir inhibited the production of
MNV RNA, also in a dose-dependent manner (EC50  10 
 1
M) (Fig. 3). Furthermore, levels of MNV RNA were reduced by
	2 log10 when cells were treated with	12.5M rupintrivir. This
inhibitory effect was, however, less pronounced than against the
Norwalk replicon; little adverse effect on the host cell was noted
(CC50 77
 7 M).
Rupintrivir has an inhibitory effect on a GII norovirus 3C-
like protease.The effect of rupintrivir on the recombinant 3C-like
protease of a GII norovirus (strain Hu/NLV/Dresden174/pUS-
NorII/1997/GE) was next assessed. This enzyme has about 63%
amino acid sequence identity to the 3C-like protease of the GI
Norwalk virus. The GII protease cleaved the FRET substrate dab-
cyl-KDEFELQ2GPALT(D-edans)-amide (corresponding to the
NS3/NS4 site) with kcat 3.25
 1.03 min
1, Km 188.2
 69.8
M, and kcat/Km 17.27 10
3 M1 min1. This activity is low,
albeit somewhat higher than that described by Chang et al. (16),
for 3C-like proteases of various other norovirus strains and for
other substrates. In our assay, the addition of 60% glycerol was
necessary to observe enzyme activity, as previously described (16).
This excessive glycerol concentration led to a high viscosity of the
assay buffer solution and is the likely cause of the large standard
deviations in the kinetic constants. The errors introduced by the
high viscosity of the assay buffer were estimated to be larger than
those due to inner-filter effects in the fluorescence measurements
in the 96-well plate (28, 29); hence, no attempts were made to
correct for the latter.
To characterize the inhibitory activity of an irreversible inhib-
itor such as rupintrivir, which binds covalently to the catalytic
cysteine of the protease, the rate of inactivation, k3, should be
determined in addition to Ki. This proved difficult, though, be-
cause of the relatively low enzyme activity, as mentioned above.
Therefore, we determined instead the ratio kobs/[I] (see Materials
and Methods). Using this approach, rupintrivir was found to in-
hibit the norovirus 3C-like protease with kobs/[I] 12.6
 3M
1
s1, indicating a weak but significant inhibitory activity of the
compound.
The fact that rupintrivir is active against noroviruses belonging
to genogroup I (Norwalk virus; EC50 0.32
 0.13 M; EC90
1.5 
 0.3 M) and genogroup V (MNV; EC50  13 
 5 M by
CPE reduction and 10
 1.6 M by qRT-PCR), as well as against
the recombinant 3C-like protease of a GII norovirus (kobs/[I] 
12.6 
 3 M1 s1), suggests that the drug exerts cross-genotypic
anti-norovirus activity and will thus most likely be effective
against the clinically relevant human norovirus strains (values
given are means
 standard deviations [SD] from four indepen-
dent experiments, except for MNV qRT-PCR, where two inde-
pendent experiments were performed).
Molecular modeling shows fitting of rupintrivir in the Nor-
walk virus protease-active site. As rupintrivir was developed as
an inhibitor of the 3C protease of human rhinoviruses (7, 8), we
assessed its potential of inhibiting the 3C-like protease of Norwalk
virus by molecular modeling, based on the crystal structure of the
free enzyme (11). The active site of the Norwalk virus protease
bears similarities to that of the enterovirus 3C proteases (30, 31);
the catalytic triad is formed by residues Cys139, His30, and Glu54
(Fig. 4). The rupintrivir molecule can be placed in the substrate-
binding pocket of the protease (Fig. 4A), with the covalent bond
formed between the C atom of its vinylogous ester moiety and
the nucleophilic Cys139 serving as one of the anchor points. An-
other anchor point is the hydrogen-bonding interaction between
the lactam oxygen of the P1 substituent and conserved His157 in
the S1 pocket (Fig. 4B). The fluorobenzyl substituent in the P2
position of the inhibitor fits smoothly into the enzyme’s S2 pocket,
the walls of which are formed by residues Glu54, Ile109, and
Gln110. According to our model, the main-chain amides and car-
bonyl oxygens of rupintrivir can make several hydrogen bonds
with the target protease. Judging from this interaction model, the
FIG 3 Antiviral activity of rupintrivir against MNV as quantified by (i) virus-
induced cytopathic effect (CPE) reduction assay using a colorimetric method
(MTS) and (ii) measuring viral RNA levels by means of qRT-PCR. Potential
cytotoxic effects were assessed in parallel. Results are mean values (
SEM)
from 2 to 4 independent experiments.
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observed inhibitory activity of rupintrivir against the norovirus
3C-like protease can be explained.
Combination of rupintrivir with polymerase inhibitors
2CMC and T-705 has an additive antiviral effect. We demon-
strated recently that 2=-C-methylcytidine (2CMC) and favipiravir
(T-705) inhibit in vitro norovirus replication (15, 32); both mol-
ecules are inhibitors of viral RNA-dependent RNA polymerases
(RdRp). We assessed the combined antiviral effects of rupintrivir
with 2CMC and T-705 in the Norwalk replicon system. 2CMC
inhibited the replication of the Norwalk replicon with an EC50 of
18
 4 M (33), while T-705 had modest activity (EC50 of 287

98 M [our unpublished data]). The mean volume of synergy/
antagonism observed was 29 M2% (17 to 41 M2%, 95% confi-
dence interval) for the 2CMC-rupintrivir combination and 15
M2% (0 to 30 M2%, 95% confidence interval) for the T-705-
rupintrivir combination. Hence, both combinations resulted in
an overall additive antiviral activity (Fig. 5), which is expected of
compoundswhosemechanismof action is distinct and that do not
interfere with each other’s metabolism or mechanism of action.
Rupintrivir was initially developed as an intranasal product to
treat rhinovirus infections (7, 8). Given its poor oral bioavailabil-
ity, the molecule does not have the ideal pharmacokinetics profile
for a prophylactic approach to prevent norovirus infections. No-
roviruses are typically involved in extensive outbreaks in semi-
closed environments, where person-to-person transmission is
usually the main route of transmission. Yet, noroviruses often
cause prolonged and severe and potentially even life-threatening
infections in elderly and immunocompromised individuals (34,
35). Rupintrivir could thus be relevant as a starting point for fur-
ther drug design activities toward a molecule with sufficient po-
tency and pharmaceutical properties to be useful in the treatment
of such risk populations.
In conclusion, we here show that the protease inhibitor rupin-
trivir exerts antiviral activity against two different genogroups of
FIG 4 Structural model of the complex between rupintrivir and the 3C-like protease of Norwalk virus. (A) Binding of rupintrivir to the substrate-binding
site of Norwalk virus 3CLpro. The electrostatic potential at the surface of the protein is displayed; red, negative potential; blue, positive potential. (B)
Details of the proposed interactions between rupintrivir (green sticks, with oxygen in red and nitrogen in blue) and the Norwalk virus 3C-like protease
(gray sticks, with oxygen in red and nitrogen in blue). Proposed hydrogen bonds are indicated as red dashed lines, with distances in Å. The orientation
is the same as that for panel A.
FIG 5 Antiviral effect of the combination of either rupintrivir and 2CMC (A) or rupintrivir and T-705 (B). Values in the zero plane indicate additive
activity; a surface below the zero plane indicates antagonism; over 20% above the plane indicates synergism. Results are mean values from 2 independent
experiments.
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norovirus and inhibits the protease of yet another genogroup. It is
therefore very likely that this molecule is able to inhibit the clini-
cally relevant GI and GII noroviruses (which cannot be cultured).
Our findings suggest that the design of protease inhibitors of no-
roviruses could be a successful approach for the treatment/pre-
vention of norovirus infections.
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